CLL Support Association
9,991 members15,616 posts

Thyroid side effect from Checkpoint inhibitors (PD-1/PD-L1)

A heads up alert to patients considering or now using Therapies containing PD-1 or PD-L1 Checkpoint inhibitors.

Quote from article: "The risk of immunotherapy-related destructive thyroiditis requires close patient monitoring and can cause permanent hypothyroidism"


3 Replies

Thank you ThreeWs.



Thank you WWW.

I am wondering if anyone is having thyroid issues with either Ibrutinib or Acalabrutinib?

I was warned by my MD Anderson consultant to carefully have my thyroid and metabolism watched when I started (any) treatment. I gained 10 lbs in 6 weeks on Acalabrutinib without change in diet or activity level. My trial doctor (NIH) says they know of no thyroid/metabolism link with the drug. Any thoughts?



Acalabrutinib is a much more specific BTK inhibitor than Ibrutinib which has demonstrated fewer adverse side effects than Ibrutinib. There are 3 main side effects listed in this recent paper for Acalabrutinib in which weight gain is one. No mention for explanation which does not rule out thyroid interaction. We will have to wait to see if any correlation is revealed. If you were warned to get your thyroid checked it is almost certain that a suspicion without proof is afoot.


1 like

You may also like...